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Abstract
Sepsis, despite recent therapeutic progress, still carries unaccep-
tably high mortality rates. The adrenergic system, a key modulator
of organ function and cardiovascular homeostasis, could be an
interesting new therapeutic target for septic shock. β-Adrenergic
regulation of the immune function in sepsis is complex and is time
dependent. However, β2 activation as well as β1 blockade seems
to downregulate proinflammatory response by modulating the
cytokine production profile. β1 blockade improves cardiovascular
homeostasis in septic animals, by lowering myocardial oxygen
consumption without altering organ perfusion, and perhaps by
restoring normal cardiovascular variability. β-Blockers could also
be of interest in the systemic catabolic response to sepsis, as they
oppose epinephrine which is known to promote hyperglycemia,
lipid and protein catabolism. The role of β-blockers in coagulation
is less clear cut. They could have a favorable role in the septic pro-
coagulant state, as β1 blockade may reduce platelet aggregation
and normalize the depressed fibrinolytic status induced by adre-
nergic stimulation. Therefore, β1 blockade as well as β2 activation
improves sepsis-induced immune, cardiovascular and coagulation
dysfunctions.  β2 blocking, however, seems beneficial in the
metabolic field. Enough evidence has been accumulated in the
literature to propose β-adrenergic modulation, β1 blockade and β2
activation in particular, as new promising therapeutic targets for
septic dyshomeostasis, modulating favorably immune, cardio-
vascular, metabolic and coagulation systems.
Introduction
Sepsis still places a burden on the healthcare system, with an
annual increase in incidence of about 9% and a mortality of
about 25% and up to 60% when shock is present [1,2].
Uncontrolled systemic inflammatory response is the hallmark
of sepsis and contributes to the development of organ
dysfunction and shock [3]. The exact mechanisms of cardio-
vascular failure following severe infection, however, remain
poorly elucidated. The adrenergic system is a key modulator
of organ function and cardiovascular homeostasis. These
receptors are widely distributed in the body, including in
circulating immune cells, vessels, the heart, airways, lungs,
adipose tissues, skeletal muscles, and brain. Furthermore,
β-adrenergic modulation is a frequent therapeutic intervention
in the intensive care setting [4] – addressing the issue of its
consequences in sepsis.
The present review summarizes current knowledge on the
effects of β-adrenergic agonists and antagonists on immune,
cardiac, metabolic and hemostasis functions during sepsis. A
comprehensive understanding of this complex regulation
system will enable the clinician to better apprehend the
impact of β-stimulants and β-blockers in septic patients.
β β-Adrenergic receptor and signaling cascade
The  β-adrenergic receptor is a G-protein-coupled seven-
transmembrane domain receptor. There are three receptor
subtypes: β1, β2 and β3. β1-receptors and β2-receptors are
widely distributed, but β1-receptors predominate in the heart
and β2-receptors are mainly found in smooth muscles such as
vessels and bronchus. Table 1 presents details of the
β-adrenergic system. Mixed β1β2-agonists include
epinephrine and isoproterenol, selective β1-agonists include
dobutamine, norepinephrine and dopamine, and selective β2-
agonists include salbutamol, terbutaline and dopexamine.
Upon activation by specific agonists, activated Gs proteins
increase intracystosolic cAMP via an adenylate cyclase-
dependent pathway [5]. cAMP activates protein kinase A,
which in turn phosphorylates numerous targets in the cell
such as transmembrane channels, and modulates nucleus
transcription via the Ras, Raf, MEK and ERK pathways [6].
The β-receptor itself can be phosphorylated by protein kinase
A, inducing its uncoupling from the G protein (acute
response) and its internalization (chronic response) – the
whole process leading to a downregulation of β-adrenergic
signaling.
β β-Adrenergic-mediated immune modulation
Immune response to sepsis
By definition, sepsis corresponds to a syndrome of systemic
inflammatory response triggered by invading pathogens [7].
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In bone marrow tissues, sepsis is associated with a shift in
the myelopoietic production towards the monocyte lineage, at
the expense of the granulocytic lineage [8]. Activated
mononuclear cells release a broad variety of proinflammatory
cytokines, including IL-1, IL-6, TNFα, IL-12, IL-15 and IL-18,
as well as the so-called late mediators, high mobility group
box 1 and macrophage migration inhibitory factor [3]. Generally,
the synthesis of proinflammatory cytokines is mediated by
NFκB. In parallel, a physiologic counter-inflammatory
response is initiated with the release of IL-10, IL-1-receptor
antagonist and soluble TNFα-receptor among various anti-
inflammatory mediators. Mononuclear cells are subsequently
reprogrammed, allowing the inflammation to be turned off. In
addition, following the initial hyperinflammatory response,
immune cell apoptosis occurs, taking part in the secondary
impairment of immune function. Apoptosis concerns mainly B
lymphocytes and CD4+ cells, as well as dendritic cells and
epithelial cells. It appears that, apart from direct immune cell
stock depletion, apoptotic bodies induce macrophage anergy
and favor anti-inflammatory cytokine secretion [9].
Sepsis is therefore characterized by a balance between pro-
inflammatory signals and anti-inflammatory signals to immuno-
effector cells [10]. Excessive systemic inflammation may favor
the development of organ failure, and excess anti-
inflammatory mediators may compromise the local response
to infection. This issue has not yet been elucidated, and the
ambivalence of immune response in sepsis reflects the
difficulty of finding therapeutic targets for immunomodulation.
β β-Adrenergic system and immune modulation
The β-adrenergic system is a well-known powerful modulator
of the immune system [11]. Lymphoid organs such as the
spleen, thymus, lymph nodes and bone marrow are predomi-
nantly innervated by the sympathetic system. The majority of
lymphoid cells express β-adrenergic receptors on their
surface, with the exception of T-helper type 2 (Th2) cells. The
density of cell surface receptors varies with cell type, natural
killer cells having the highest density. The efficiency of
receptor coupling with adenylate cyclase also differs among
immune cells, with natural killer cells and monocytes being
the most responsive cells.
In bone marrow, monocytic production appears to be under
the influence of sympathetic activation via β2-receptors. Indeed,
monocytes have an increased sensitivity to epinephrine. Upon
adrenergic stimulation, monocytes differentiate into mature
macrophages [12] that are functionally different in their cyto-
kine response [13].
Immune cell apoptosis is at least partly mediated by
catecholamines, via α-adrenergic and β-adrenergic pathways.
Nonspecific and specific β2 blockade induce splenocyte
apoptosis [14]. Epinephrine also exerts apoptosis, however,
Table 1
The β β-adrenergic system
Target Sympathetic receptor
Heart Cardiac muscle β1β2 increases
Heart rate β1β2 increases
Blood vessels Vascular smooth muscle β2 relaxes
Smaller coronary arteries β2 dilates
Hepatic artery β2 dilates
Arteries to skeletal muscle β2 dilates
Veins β2 dilates
Respiratory system Smooth muscles of bronchioles β2 relaxes
Digestive system Smooth muscle of gastrointestinal tract β2 relaxes
Sphincters of gastrointestinal tract β2 contracts
Kidney β1 enhances renin secretion
Liver β2 increases glycogenolysis, gluconeogenesis
Adipose cells β1β3 stimulates lipolysis
Urinary system Detrusor  β2 relaxes
Sphincter β2 relaxes
Reproductive system Uterus β2 relaxes 
Nervous system Ciliary muscles β2 relaxessuggesting that β blockade creates an imbalance towards the
α-adrenergic pathway that is proapoptotic [15].
Catecholamines, via a β2-mediated pathway [16], down-
regulate the synthesis of proinflammatory cytokines such as
TNFα, IL-6 and IL-1 [17-19], and upregulate synthesis of anti
inflammatory cytokines (for example, IL-10) [18,19]. The
pattern of cytokine production in sepsis is dependent on the
CD4+ T-helper type 1 (Th1) and Th2 balance [20] (Figure 1).
T-helper cells coordinate the adaptative immune response
towards cellular or humoral response by secreting different
subsets of cytokines. Subclass Th1 cells promote cellular
immunity by secreting IFNγ, IL-2 and transforming growth
factor beta, by activating macrophages and natural killer cells,
and by producing inflammatory mediators. Subclass Th2 cells
promote humoral response and synthesize primarily IL-4 and
IL-10. Th2 response therefore inhibits macrophage activation,
T-cell proliferation and proinflammatory cytokine production
[11]. Th1 cells express β2-adrenergic receptors on their
surface, whereas Th2 cells do not [21]. Sepsis-induced β2-
adrenergic stimulation therefore selectively inhibits Th1
function and favors the Th2 response.
The immunosuppressive effects of catecholamines may be
attenuated in prolonged septic shock. Indeed, epinephrine
did not alter TNFα or IL-10 in patients in septic shock [22].
β-Adrenergic regulation of the immune function in sepsis is
therefore complex and is time dependent. Nonselective β
blockade by propranolol inhibited the mobilization and
activation of natural killer cells [23]. Two studies in septic
mice showed that propranolol upregulated Th1-mediated
IFNγ production and downregulated the Th2-mediated IL-6
synthesis [15,24]. In these experiments, however, propranolol-
treated animals had a greater mortality rate. In another study
on severely burnt children, propranolol administration
significantly decreased serum TNF and IL-1β concentrations,
and did not increase mortality [25]. Interestingly, in septic
rats, selective β1 blocking by esmolol decreased circulating
TNFα and IL-1β concentrations [26]. Similarly, landiolol,
another selective β1-blocker, also decreased circulating levels
of TNFα, IL-6, and high mobility group box 1 [27]. While
IL-10 production was not altered by β blockade [28], it was
increased by β-agonists [18,19]. The mechanisms by which
β1-adrenoceptor blockade modulates cytokine production
remain unknown.
Counteracting the adrenergic storm of sepsis, β-blockers
modulate cytokine profile production. β2-blockers seem to
induce a proinflammatory profile, whereas β1 blockade has
the opposite effect. The numerous studies conducted,
however, show conflicting results on sepsis outcome. This
inconsistency reflects the difficulty to apprehend the
beneficial and harmful effects of the modulation of both
proinflammatory and anti-inflammatory processes.
β β-Adrenergic-mediated cardiovascular
modulation
Physiopathology of myocardial dysfunction in sepsis
Myocardial depression, defined as diminution of the left
ventricular ejection fraction, occurs in about 50% of patients
with septic shock [29]. The depression is characterized by
both left and right ventricular dysfunction. Systolic dys-
function occurs early in shock with lower ejection fraction and
acute ventricle dilatation. Interestingly, patients who do not
dilate their ventricles have worse prognosis than those with
acute and reversible dilated cardiomyopathy. Diastolic dys-
function may also be altered, with slower ventricular filling on
echocardiography and altered relaxation. Whether diastolic
dysfunction carries a poor prognosis in sepsis is still unclear.
Of note, in spite of the myocardial depression, following
adequate fluid resuscitation, cardiac output remains high until
death or recovery [30]. The mechanisms of myocardial
depression are multiple [31], including microvascular
abnormalities, autonomic dysregulation, metabolic changes,
mitochondrial dysfunction and cardiomyocyte apoptosis [32].
Beside excessive adrenergic nervous system activation,
patients with septic shock receive a substantial amount of
exogenous catecholamines. This adrenergic storm is thought
to be detrimental to cardiac function, as it is in chronic heart
failure [33]. Studies have shown that intracystosolic cAMP
levels are attenuated in sepsis after β-adrenergic stimulation
[34], leading to decreased myocardial performance. Sepsis
downregulates  β-adrenoceptors by phosphorylation and
internalization, reducing the density of receptors on the cell
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Figure 1
T-helper type 1 and T-helper type 2 balance and the adrenergic
system. Naive CD4+, T-helper type 0 (Th0) cells are bipotential and are
precursors of T-helper type 1 (Th1) cells and T-helper type 2 (Th2)
cells. IL-12, produced by antigen-presenting cells, is the major inducer
of Th1 differentiation. Th1 and Th2 responses are mutually inhibitory.
IL-12 and IFNγ therefore inhibit Th2 cell activity, while IL-4 and IL-10
inhibit the Th1 response. The stimulation of β-adrenergic receptors
potently inhibits the production of IL-12 by antigen-presenting cells,
and thus inhibits the development of Th1 cells while promoting Th2 cells.surface [35,36]. Uncoupling of β-adrenoceptors alters trans-
duction pathways [37] via decreased expression of Gs
proteins and increased inhibitory activity of Gi proteins [38].
The sustained adrenergic stimulation per se may trigger cyto-
kine production by cardiomyocytes [39].
From another viewpoint, physiological oscillations in heart
rate and blood pressure are directly correlated to the activity
of the autonomic nervous system. Bedside analysis of heart
rate variability may help in investigating the vagal to sympathetic
balance [40]. In critically ill patients, the loss of heart rate
variability may contribute to the progression of organ dys-
function [41] and is associated with increased risk of death
[42-44]. Sepsis is often characterized by altered cardio-
vascular variability, and particularly by impaired sympathetic
control on heart and vessel tone [45-47]. The loss in sympa-
thetic modulation of the cardiovascular system preceded
shock in both experimental sepsis and clinical sepsis [47,48].
β β-Adrenergic modulation and sepsis-induced
myocardial dysfunction
The first studies of adrenergic modulation in septic shock
were published in the late 1960s [49,50]. These studies have
evidenced that septic shock induced excessive β-adrenergic
stimulation, altering splanchnic and pulmonary circulation.
Infusion of propranolol then improved the arterial pressure
and pH, and eventually improved survival.
Following the same line of evidence, excessive β1 stimulation
by dobutamine increased the mortality rate in critically ill
patients [51]. On the other hand, treatment with isoproterenol,
a nonselective β-stimulant, in β1-adrenoceptor knockout mice
prevented apoptosis in the myocardium [52]. These findings
suggest that β2-adrenergic stimulation protects myocardial
function during sepsis. In septic rats, esmolol, a selective
β1-antagonist, improved myocardial function and oxygen
consumption [26]. There was also evidence of improved
relaxation and an increase of end-diastolic volume. In patients
with sepsis, esmolol lowered the heart rate and cardiac
output without altering whole-body oxygen consumption,
suggesting an increase in tissue oxygen extraction [53].
Organ perfusion also remained unaltered. In another study,
oral metoprolol induced a significant increase in arterial pH
and decreased arterial lactate concentrations [54]. In 22.5%
of the metoprolol-treated patients, however, vasopressor
therapy had to be increased.
On the sympathovagal modulation level, specific β1 blockade
by metoprolol and atenolol may restore heart rate variability in
conditions such as coronary artery disease [55] or chronic
heart failure [56,57]. Whether selective β1-antagonist may
restore normal cardiovascular oscillations in sepsis deserves
to be investigated.
Evidence for a beneficial effect of β blockade is far more clear
cut than for immune modulation. Indeed, β1 blockade seems
beneficial to myocardial function in sepsis, improving its
diastolic function, oxygen extraction and consumption. β2
stimulation should be respected as some evidence shows a
protective action. Selective β1 blockade could also maintain
global cardiovascular homeostasis by restoring adequate
sympathovagal balance.
Metabolic effects of β β-adrenergic modulation
Sepsis-associated metabolic dysfunction
Sepsis is associated with a systemic adaptative catabolic
response [58] that is characterized by increased resting
energy expenditure, extensive protein and fat catabolism,
negative nitrogen balance, hyperglycemia, and progressive
loss of lean body mass. Although this response to stress
might be adaptative in the early stage, when sustained it may
cause malnutrition and immunosuppression and may promote
organ dysfunction [59] and death [60].
Counteracting hyperglycemia may favorably impact morbi-
mortality [61,62]. Indeed, increased extracellular glucose
impairs the host response to infection, increases oxidative
stress, and favors procoagulant factors, sympathetic hyper-
activity, and the proinflammatory response [63]. Hyper-
glycemia is multifactorial, and may result from enhanced
counter-regulatory hormones glucagon, cortisol and catechol-
amines that promote hepatic glycogenolysis and gluconeo-
genesis, as well as peripheral insulin resistance [64].
Skeletal muscle protein loss is multifactorial, caused by an
imbalance between an increased rate of muscle protein
degradation and increased synthesis of proteins such as
cytokines [65]. The decrease in basal muscle protein
synthesis seems partly correlated by the availability of a
branched-chain amino acid, leucine [66]. An increased
leucine concentration stimulates muscle protein synthesis
[67]. Sepsis is associated with muscle leucine resistance, via
a mechanism not yet clearly understood.
At the cellular level, sepsis is characterized by impaired
cellular respiration. Numerous studies have shown in septic
shock that the tissue partial pressure of oxygen is normal or
high, and cells are unable to utilize oxygen. This cytopathic
hypoxia is a direct consequence of mitochondrial dysfunction
[68], which is at least partly related to excessive release of
nitric oxide following overexpression of inducible nitric oxide
synthase [69].
Adrenergic modulation of sepsis-associated metabolic
dysfunction
The increase in protein and lipid catabolism and hyper-
glycemia are both partly mediated via β2-adrenergic signaling
[70,71]. Epinephrine induces insulin resistance [72] and
enhances glucose hepatic production [73,74], but norepi-
nephrine or dobutamine does not [75]. Epinephrine-induced
gluconeogenesis increases hepatic oxygen consumption. As
epinephrine also decreases hepatosplanchnic blood flow,
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Norepinephrine, on the contrary, increases hepatic blood flow
and does not promote gluconeogenesis due to its lack of β2
activity. Dobutamine seems to increase blood flow but also
increases splanchnic oxygen consumption [78,79]. Two
studies conducted on healthy volunteers showed that
epinephrine, although elevating the global metabolic rate, did
not increase muscle proteolysis with regard to circulating
leucine levels [77,80]. Basal metabolic rates of septic
patients are far from those of healthy volunteers, however,
and these results cannot be directly extrapolated.
In experimental sepsis, nonspecific β blockade by propranolol
reduced the plasma glucose concentration via a decrease in
endogenous glucose production [81,82]. Propranolol im-
proved the nitrogen balance, suggesting reduced muscle
proteolysis [83]. A key trial by Herndon and colleagues
showed that propranolol treatment in severely burnt children,
a condition associated with hypercatabolism and severe
muscle wasting, attenuated the resting energy expenditure
and reversed muscle protein catabolism [84]. By contrast,
these effects were not seen with β1-selective blockers [53].
There is little information on the effects of β-adrenergic
modulation on sepsis-associated cytopathic dysoxia. Never-
theless, in chronic heart failure and myocardial infarction,
carvedilol exerted cardiac mitochondrial protection via
inhibition of mitochondrial permeability transition [85,86].
In sepsis-induced metabolic disorder, β2 antagonization is
beneficial – lowering gluconeogenesis, hyperglycemia, proteo-
lysis and resting energy expenditure. β1-blockers seem to
lack any activity on metabolism modulation.
β β-Adrenergic modulation and the coagulation
system
β β-Adrenergic modulation of platelet function
Platelets play a complex role in sepsis – they contribute to
thrombus formation and release mediators of neutrophils and
macrophages, and ensure vascular tone and endothelial
integrity [87]. Sepsis is characterized by thrombocytopenia
and altered platelet function. Studies in patients with sepsis
showed variably reduced [88] or increased [89] platelet
aggregability, and showed increased β-thromboglobulin, a
marker of activated platelets [90].
Platelets express on their surface adrenergic receptors,
which can modulate their functions [91]. α2-Adrenoceptor
stimulation enhances aggregability via increased intra-
cystosolic calcium and decreased cAMP, whereas β2-
adrenoceptors reduce aggregability by stimulating cytosolic
cAMP. A vast majority of in vivo and in vitro studies showed
that epinephrine activated platelet aggregation via the α2-
mediated pathway [91,92]. The effects of β blockade are
more controversial. Indeed, β2 inhibition may enhance platelet
activation by unopposed α2 stimulation. Chronic β-adrenergic
blockade, however, could transregulate the α-adrenergic
signal by reducing the density of α2-adrenoceptors on the
cell surface and by impairing the signaling cascade [93]. In
patients with ischemic heart disease, propranolol reduced
platelet aggregation. Interestingly, in hypertensive patients, β1
blockade also reduced platelet aggregation, although the
underlying mechanisms remain unclear [94].
These results were obtained in healthy volunteers and in
patients with hypertension or ischemic heart disease, not in
sepsis patients. The effects of catecholamines on in vivo
septic platelet activation deserve to be investigated.
β β-Adrenergic modulation of coagulation in sepsis
Sepsis induces an imbalance between exaggerated coagula-
tion activation and inhibition of fibrinolysis. Plasma tissue
factor and von Willebrand factor levels are increased, activat-
ing coagulation in conjunction with activated factor VII.
Amplification by the coagulation cascade leads to thrombin
formation, and then to fibrin formation [95]. Thrombi formation
leads to endothelial damage, exposing more tissue factor and
accentuating the coagulation activation. Endotoxins induce
endothelial cell apoptosis by macrophage activation, further
damaging the endothelium [96].
Sepsis also downregulates the physiologic anticoagulant
proteins, tissue factor pathway inhibitor, antithrombin and
activated protein C. Indeed, tissue factor pathway inhibitor
activity is impaired as a result of glycosaminoglycan down-
regulation. Circulating antithrombin levels are decreased by
impaired synthesis and increased consumption. Liver protein C
synthesis and activation are impaired. Finally, as fibrin clots
are generated by the coagulation process, the fibrinolytic
system degrades fibrin by its key enzyme, plasmin. Plasmin
formation from plasminogen is mainly activated by tissue
plasminogen activator and inhibited by plasminogen activator
inhibitor 1. In response to an increased circulating TNFα and
IL-1β concentration, plasminogen activator inhibitor 1 produc-
tion is enhanced, leading to impaired fibrinolysis. The net
result in sepsis is a procoagulant state, where coagulation is
activated and amplified, and physiologic anticoagulation and
fibrinolytic mechanisms are impaired.
To the extreme, disseminated intravascular coagulation occurs,
promoting microcirculation alteration – which is one of the key
factors of multiple organ failure. Furthermore, as inflammation
interacts with coagulation, complement activation by sepsis
leads to products such as C3a, C4a and C5a, which may
promote procoagulant activity [97]. C5a induces tissue factor
on endothelial cells, C5b stimulates prothrombinase activity,
and C4b affects the protein S system. Antagonization of C5a
by specific antibodies in septic rats reduced procoagulant
activity and prevented fibrinolysis impairment [98].
Epinephrine increases the factor VIII concentration [92]. This
effect of epinephrine remains unaltered by selective
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mechanism. In addition, salbutamol and not norepinephrine
reproduced epinephrine hemostatic effects. Epinephrine also
increased von Willebrand factor concentrations, an effect
abolished by nonselective β blockade [100]. Adrenergic
agonist did not affect tissue factor concentrations, but
epinephrine might increase the procoagulant activity by
promoting P-selectin expression on the platelet surface
[101]. There is no information on adrenergic modulation of
tissue factor pathway inhibitor, antithrombin or activated
protein C.
Adrenergic stimulation has been known to increase fibrino-
lytic activity since the 1960s [102], due to stimulated tissue
plasminogen activator release by specific β2-adrenoceptor
activation. β1 activation, on the other hand, did not modify
tissue plasminogen activator or plasminogen activator
inhibitor 1 levels [103] – but may decrease fibrinolysis via
reduction of prostacyclin synthesis by endothelial cells [104].
Accordingly, nonselective β-blockers reduced tissue plas-
minogen activator concentrations and decreased fibrinolysis,
but β1-blockers did not. It is thought that β1-blockers could
normalize the depressed fibrinolytic status induced by
β1-adrenergic stimulation [103].
Complement modulation by β blockade or β activation has
not been investigated. Hepatic complement clearance seems
to be influenced by the adrenergic system, however, as
propranolol restores Kupffer cell clearance function in vitro,
hence reducing circulating activated complement fractions
[105].
The sepsis-induced procoagulant state is therefore at least
partly mediated by the adrenergic system. β1 and β2 path-
ways, however, seem to have opposite effects. β2 blocking
could be detrimental by counteracting a β2-induced decrease
in platelet activation and improved fibrinolytic activity. β1
blockade could therefore be beneficial for the fibrinolytic
status.
Conclusion
The  β-adrenergic system has a wide range of effects in
various organ systems. Tight regulation of β1-adrenergic and
β2-adrenergic receptors may contribute to restore immune,
metabolic, cardiovascular and coagulation homeostasis.
Modulating the β-adrenergic system, and in particular
β blockade, is therefore an exciting new therapeutic
approach. The use of hypotensive drugs such as β-blockers
in severe sepsis and septic shock, however, raises justified
safety issues. Manipulation of the β-adrenergic system in
septic shock should be carefully tested in various animal
models of sepsis prior to considering its evaluation in
patients.
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